Karen Mcclorey Hackett is a journalist who writes for the Precision Vaccines Program. Her work focuses on providing updates and analysis on vaccine-related topics, including vaccine development, disease outbreaks, and public health initiatives. Her articles have also been featured in Vax-Before-Travel, a publication dedicated to vaccine news and information.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Karen Mcclorey Hackett's coverage heavily revolves around public health, vaccines, disease outbreaks, and clinical trials. She consistently cites data and government announcements in her articles. To effectively reach out to her, consider providing access to reliable and up-to-date data related to public health issues or breakthroughs in vaccine development.
Experts with a deep understanding of global health trends, clinical trial outcomes, or experience working on the front lines of disease prevention would likely capture Karen’s interest given the nature of her reporting. It is important to note that she does not have a specific geographic focus but rather covers global healthcare topics comprehensively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Chikungunya, dengue, other vaccine preventable diseases confirmed in Florida in 2024
By: Karen Mcclorey Hackett
Mpox vaccines are commercially available in September 2024
By: Karen Mcclorey Hackett
About two years ago, the World Health Organization (WHO) published a report highlighting the first-ever list of fungal priority pathogens, which included 19 fungi representing the greatest threat to public health. Since then, the WHO has not recommended a fungal vaccine but continues to encourage the development of innovative therapies.
By: Karen Mcclorey Hackett
The Chikungunya virus (CHIKV) disease was first reported in the Republic of India in 1963 and has since spread to all parts of the subcontinent, becoming endemic. This health risk is seldom discussed, with over 6 million people visiting India, including about 1.3 million people from the United States.
By: Karen Mcclorey Hackett
Vaccines prevented travel related diseases in 2024
By: Karen Mcclorey Hackett
As the respiratory syncytial virus (RSV) activity ramps up for the 2024-2025 season, more children will have access to an innovative therapy this year. Sanofi U.S. announced today that it is shipping BEYFORTU™ 50mg and 100mg injection doses to private healthcare providers in the United States.
By: Karen Mcclorey Hackett
Chikungunya, Dengue, Malaria travel vaccines offered in 2024
By: Karen Mcclorey Hackett
Pediatric influenza deaths influenced by vaccination timing, medical condition, hospital access
According to a Research Letter, Volume 30, Number 10—October 2024, published in Emerging Infectious Diseases, 53.4% of infants were infected with respiratory syncytial virus (RSV) during infancy, and 2.8% were hospitalized. The Risk factors for RSV infection during infancy, in order of contribution, were:
By: Karen Mcclorey Hackett
GSK plc recently announced topline Phase 3 clinical trial data for a combination regimen of two of its vaccines: the RSV vaccine Arexvy and Shingrix, a market-leading shingles shot. While GSK did not provide specific clinical trial (NCT05966090) data in its September 18, 2024 announcement, the company did confirm that co-administering Arexvy with Shingrix resulted in a “non-inferior immune response” compared with inoculation with the vaccines at separate visits. The vaccine combo was also well-tolerated with an “acceptable” safety profile, according to GSK.
(833) 317-6278 
